Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
CD 19+ Acute Leukemia: early-phase trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
CD 19+ Acute Leukemia: 2 US clinical trials tracked, none currently recruiting.
CD 19+ Acute Leukemia is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Seattle Children's Hospital, running 2 of these trials.
Enrollment posture brief
Registry condition cd-19-acute-leukemia
OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
CD 19+ Acute Leukemia has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for CD 19+ Acute Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
CD 19+ Acute Leukemia is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Seattle Children's Hospital
NCT02028455
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Seattle Children's Hospital
NCT03186118
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on CD 19+ Acute Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on CD 19+ Acute Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this CD 19+ Acute Leukemia page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No CD 19+ Acute Leukemia trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Seattle Children's Hospital sponsors the most CD 19+ Acute Leukemia trials on record, review their full trial history before evaluating a specific study. See Seattle Children's Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This CD 19+ Acute Leukemia condition card totals 2 registered trials; most-linked intervention T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC); top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.